A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma
NCT07527169
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
16
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Olfactory Neuroblastoma
Interventions
DRUG:
Zanzalintinib
Sponsor
M.D. Anderson Cancer Center